6 reports

ONLY ONE CETUXIMAB BIOSIMILAR IS UNDER DEVELOPMENT IN THE ##MM, RELIANCE LIFE SCIENCES' R-TPR-##, WHICH IS INVESTIGATED IN AN INDIAN-BASED PHASE III TRIAL IN HEAD AND NECK CANCER.

  • Biosimilar
  • Cancer
  • India
  • South Korea
  • Celltrion, Inc.

At least one clinical trial necessary.

  • Biosimilar
  • Cancer
  • Oncology
  • Biocon Limited
  • Celltrion, Inc.
  • Market Access of Oncology Biosimilars in the 5EU Oncology Biosimilars Marketed in the 5EU

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU Summary Market access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more stringent scientific and value assessments and economic pressures on national budgets and...

  • Cancer
  • Oncology
  • Pharmaceutical
  • Southern Europe
  • Celltrion, Inc.
  • PFIZER (& HOSPIRA)
  • NOVARTIS (& SANDOZ) - 3/3

Antibody Cancer ## ## ID No.

  • Cancer
  • Therapy
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.
  • EQUITY OFFERING

The company' s deal volume increased from one pharmaceuticals & healthcare deal in 2016 to three pharmaceuticals & healthcare deals in 2017.

  • Cancer
  • Healthcare
  • Monoclonal Antibody
  • Pharmaceutical
  • Celltrion, Inc.
  • PARTNER 1: CELLTRION INC
  • PARTNER 3: CELLTRION INC

ORChem Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s ORChem Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments,...

  • Cancer
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Celltrion, Inc.